Legal Proceedings Report • Oct 5, 2020
Legal Proceedings Report
Open in ViewerOpens in native device viewer
Cevira is a photodynamic drug-device combination product under development for non-surgical treatment of high-grade cervical dysplasia. In July 2019, Photocure announced that it had entered into a License Agreement providing Asieris Meditech Co., Ltd (Asieris) with a worldwide license to develop and commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. In July 2020, Asieris received China NMPA's approval to start a global Phase III clinical trial for APL-1702 (Cevira).
The EP 2983780 patent covering the commercial Cevira device in Europe, will expire 09 April 2034.
Cevira® is a photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade cervical dysplasia. Cevira® is easily placed on the cervix by the gynecologist and removed by the patient, with no disruption of normal daily activities. Only one or two treatments are needed.
High-grade cervical squamous intraepithelial lesions (HSIL) is a precancerous condition caused by a persistent HPV infection, a highly prevalent sexually transmitted disease resulting in approximately 10 million cases with high grade disease and > 500 000 new cases of cervical cancer each year. In China, 1- 2% of women have HSIL each year. Currently, surgical excision is the most common treatment option offered to women with cervical high-grade dysplasia. In women of childbearing age in particular there is a high medical need for a non-surgical option which preserves the cervical anatomy and function. No such medical alternative is approved to date.
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com
All trademarks mentioned in this release are protected by law and are registered trademarks of PhotocureASA
Dan Schneider President and CEO Tel: +1-609 759-6515 Email: [email protected]
Erik Dahl CFO Tel: +47 45055000 Email: [email protected]
Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.